AVITA Medical, Inc. (RCEL)
13.21
-0.12
(-0.90%)
USD |
NASDAQ |
Oct 09, 16:00
13.20
-0.01
(-0.08%)
After-Hours: 20:00
AVITA Medical Cash from Operations (Quarterly) : -3.630M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.630M |
| March 31, 2026 | -10.07M |
| December 31, 2025 | -5.474M |
| September 30, 2025 | -5.538M |
| June 30, 2025 | -10.44M |
| March 31, 2025 | -10.31M |
| December 31, 2024 | -7.062M |
| September 30, 2024 | -7.613M |
| June 30, 2024 | -12.82M |
| March 31, 2024 | -20.86M |
| December 31, 2023 | -10.68M |
| Date | Value |
|---|---|
| September 30, 2023 | -8.594M |
| June 30, 2023 | -8.896M |
| March 31, 2023 | -9.073M |
| December 31, 2022 | -2.972M |
| September 30, 2022 | -2.337M |
| June 30, 2022 | -3.408M |
| March 31, 2022 | -9.37M |
| June 30, 2021 | -3.610M |
| March 31, 2021 | -9.598M |
| December 31, 2020 | -5.824M |
| September 30, 2020 | -7.713M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 240.89M |
| Iovance Biotherapeutics, Inc. | -60.84M |
| Agenus, Inc. | -31.20M |
| Amgen, Inc. | 4.002B |
| Editas Medicine, Inc. | -29.57M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 3.947M |
| Cash from Financing (Quarterly) | 0.5013M |
| Free Cash Flow | -25.21M |
| Free Cash Flow Per Share (Quarterly) | -0.1217 |
| Free Cash Flow to Equity (Quarterly) | -4.103M |
| Free Cash Flow to Firm (Quarterly) | -2.272M |
| Free Cash Flow Yield | -6.36% |